Medulloblastoma: clinical and biologic aspects

Area of Science:

• Pediatric Oncology
• Neuro-oncology
• Cancer Biology

Background:

• Medulloblastoma is the most common primary central nervous system (CNS) tumor in children.
• Understanding the biology of medulloblastoma is crucial for developing new therapeutic strategies.
• Patient stratification into risk groups (average, poor, and potentially intermediate) is fundamental to current treatment studies.

Purpose of the Study:

• To review the evolution of medulloblastoma treatment over the past three decades.
• To highlight current therapeutic approaches, including risk stratification, radiation, and chemotherapy.
• To discuss challenges in treating specific patient subgroups, such as those with disseminated disease and very young children.

Main Methods:

• Review of current treatment protocols for medulloblastoma.
• Analysis of survival rates based on disease dissemination and patient age.
• Discussion of emerging research directions and challenges in managing treatment-related sequelae.

Main Results:

• Standard treatment for older children involves radiation and chemotherapy, with high survival rates (up to 80% 5-year disease-free survival) for nondisseminated disease using reduced-dose craniospinal irradiation.
• Preradiation chemotherapy has not demonstrated significant benefit.
• Children with disseminated disease and very young children represent challenging subgroups requiring intensified treatment approaches.

Conclusions:

• Treatment advancements have improved outcomes for some medulloblastoma patients, but challenges remain, particularly for infants and those with disseminated disease.
• Long-term survivors face significant risks of endocrinologic, cognitive, and psychological sequelae.
• Further research into the biology and novel therapeutic strategies is essential for improving outcomes and minimizing treatment toxicity.